Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

Similar articles for PubMed (Select 16365288)


Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7. Epub 2005 Dec 19.


MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.


The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.


Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

Lu X, Huang LJ, Lodish HF.

J Biol Chem. 2008 Feb 29;283(9):5258-66. Epub 2007 Dec 23.


Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.


JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.


The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW.

Blood. 2005 Nov 15;106(10):3377-9. Epub 2005 Aug 4.


Activated Jak2 with the V617F point mutation promotes G1/S phase transition.

Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M.

J Biol Chem. 2006 Jun 30;281(26):18177-83. Epub 2006 Apr 21.


JAK2, the JAK2 V617F mutant and cytokine receptors.

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN.

Pathol Biol (Paris). 2007 Mar;55(2):88-91. Epub 2006 Aug 14. Review.


Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.


Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.

Miura O, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N.

Blood. 1994 Sep 1;84(5):1501-7.


JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.


A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.

Trends Mol Med. 2005 Dec;11(12):546-54. Epub 2005 Nov 3. Review.


Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.


Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Aug 30;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. Epub 2012 Jul 26.


The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells.

Harris KW, Hu XJ, Schultz S, Arcasoy MO, Forget BG, Clare N.

Blood. 1998 Aug 15;92(4):1219-24.


JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH.

Leukemia. 2006 Jun;20(6):971-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk